85 related articles for article (PubMed ID: 11389077)
1. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
2. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
3. Role of heregulin in human cancer.
Breuleux M
Cell Mol Life Sci; 2007 Sep; 64(18):2358-77. PubMed ID: 17530167
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation.
Monje PV; Athauda G; Wood PM
J Biol Chem; 2008 Dec; 283(49):34087-100. PubMed ID: 18799465
[TBL] [Abstract][Full Text] [Related]
5. Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination.
Zanazzi G; Einheber S; Westreich R; Hannocks MJ; Bedell-Hogan D; Marchionni MA; Salzer JL
J Cell Biol; 2001 Mar; 152(6):1289-99. PubMed ID: 11257128
[TBL] [Abstract][Full Text] [Related]
6. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
7. Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha.
Hoffmann M; Schmidt M; Wels W
Cancer Immunol Immunother; 1998 Nov; 47(3):167-75. PubMed ID: 9829842
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer.
Steele TM; Tsamouri MM; Siddiqui S; Lucchesi CA; Vasilatis D; Mooso BA; Durbin-Johnson BP; Ma AH; Hejazi N; Parikh M; Mudryj M; Pan CX; Ghosh PM
Sci Rep; 2023 Jun; 13(1):9617. PubMed ID: 37316561
[TBL] [Abstract][Full Text] [Related]
9. Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization.
Magi S; Iwamoto K; Yumoto N; Hiroshima M; Nagashima T; Ohki R; Garcia-Munoz A; Volinsky N; Von Kriegsheim A; Sako Y; Takahashi K; Kimura S; Kholodenko BN; Okada-Hatakeyama M
J Biol Chem; 2018 Feb; 293(6):2206-2218. PubMed ID: 29233889
[TBL] [Abstract][Full Text] [Related]
10. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract][Full Text] [Related]
11. Coordinate transcriptional regulation of ErbB2/3 by C-terminal binding protein 2 signals sensitivity to ErbB2 inhibition in pancreatic adenocarcinoma.
Chougoni KK; Park H; Damle PK; Mason T; Cheng B; Dcona MM; Szomju B; Dozmorov MG; Idowu MO; Grossman SR
Oncogenesis; 2023 Nov; 12(1):53. PubMed ID: 37949862
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3.
Nilvebrant J; Astrand M; Löfblom J; Hober S
Cell Mol Life Sci; 2013 Oct; 70(20):3973-85. PubMed ID: 23728098
[TBL] [Abstract][Full Text] [Related]
13. Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality.
Clairefond S; Ouellet V; Péant B; Barrès V; Karakiewicz PI; Mes-Masson AM; Saad F
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918389
[TBL] [Abstract][Full Text] [Related]
14. Trans-activating mutations of the pseudokinase ERBB3.
Koivu MKA; Chakroborty D; Airenne TT; Johnson MS; Kurppa KJ; Elenius K
Oncogene; 2024 May; ():. PubMed ID: 38806620
[TBL] [Abstract][Full Text] [Related]
15. Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study.
Winter P; Fuksiewicz M; Jagiello-Gruszfeld A; Nowecki Z; Kotowicz B
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001709
[TBL] [Abstract][Full Text] [Related]
16. Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells.
Negrón-Vega L; Cora EM; Pérez-Torres M; Tang SC; Maihle NJ; Ryu JS
Biochem Biophys Rep; 2022 Sep; 31():101326. PubMed ID: 36039113
[TBL] [Abstract][Full Text] [Related]
17. Neuregulins in Neurodegenerative Diseases.
Ou GY; Lin WW; Zhao WJ
Front Aging Neurosci; 2021; 13():662474. PubMed ID: 33897409
[TBL] [Abstract][Full Text] [Related]
18. Thirty Years of HER3: From Basic Biology to Therapeutic Interventions.
Haikala HM; Jänne PA
Clin Cancer Res; 2021 Jul; 27(13):3528-3539. PubMed ID: 33608318
[TBL] [Abstract][Full Text] [Related]
19. Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.
Geissler A; Ryzhov S; Sawyer DB
Clin Sci (Lond); 2020 Oct; 134(19):2623-2643. PubMed ID: 33063822
[TBL] [Abstract][Full Text] [Related]
20. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Romaniello D; Marrocco I; Belugali Nataraj N; Ferrer I; Drago-Garcia D; Vaknin I; Oren R; Lindzen M; Ghosh S; Kreitman M; Kittel JC; Gaborit N; Bergado Baez G; Sanchez B; Eilam R; Pikarsky E; Paz-Ares L; Yarden Y
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
